Stay updated with breaking news from Pete Schmidt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept. 11, 2023 -- Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect the...
Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript August 12, 2023 Operator: Welcome to the Invivyd Second Quarter 2023 Business and Financial Results Update Call. I will now turn the call over to Gabriella Linville-Engler, Director of External Communications. Gabriella Linville-Engler: Thank you for joining us today. Before we get started, I want to tend […]
Operator: Thank you for standing by and welcome to the Invivyd 2022 Year End Financial Results Update Call. As reminder, today's call is being recorded.
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term... | March 23, 2023
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term designation of an additional monoclonal antibody against SARS-CoV...